Drug Trial Radar · NCT06934226
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
752
Actual
Start
Apr 15, 2025
Primary completion
Nov 17, 2025
Study completion Aug 20, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Conditions
- Plaque Psoriasis
Interventions
JNJ-77242113Drug
JNJ-77242113 will be administered orally.
Matching Placebo to JNJ-77242113Drug
Matching placebo will be administered orally.
UstekinumabDrug
Ustekinumab will be administered subcutaneously.
Matching Placebo to UstekinumabDrug
Matching placebo will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16Time frame: Week 16
- JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16Time frame: Week 16
Locations
160 sites in 13 countries. Site status is shown where the registry gives one.
Cahaba Research Inc
Birmingham, Alabama
California Dermatology & Clinical Research Institute
Encinitas, California
T Joseph Raoof Md Inc
Encino, California
First OC Dermatology
Fountain Valley, California
Dermatologist Medical Group of North County, Inc.
Oceanside, California
NorCal Clinical Research
Rocklin, California
Integrative Skin Science and Research
Sacramento, California
MedDerm Associates
San Diego, California
Southern California Dermatology
Santa Ana, California
Olive View-UCLA Education & Research Institute
Sylmar, California
University of Conn Health Center
Farmington, Connecticut
Driven Research LLC
Miami, Florida
Bioclinical Research Alliance Inc.
Miami, Florida
Renstar Medical Research
Ocala, Florida
Forcare Clinical Research Inc
Tampa, Florida
Hamilton Research LLC
Alpharetta, Georgia
Northshore Medical Group
Skokie, Illinois
Indiana Clinical Trial Center
Plainfield, Indiana
University of Iowa
Iowa City, Iowa
Equity Medical
Bowling Green, Kentucky
Tufts Medical Center
Boston, Massachusetts
Metro Boston Clinical Partners
Brighton, Massachusetts
The Derm Institute of West Michigan
Caledonia, Michigan
Henry Ford Hospital
Detroit, Michigan
Hamzavi Dermatology
Fort Gratiot, Michigan
Somerset Skin Centre
Troy, Michigan
Minnesota Clinical Study Center
New Brighton, Minnesota
Cleaver Dermatology
Kirksville, Missouri
MediSearch Clinical Trials
Saint Joseph, Missouri
Mount Sinai Doctors Dermatology
New York, New York
Sadick Research Group
New York, New York
Wilmington Dermatology Center
Wilmington, North Carolina
Optima Research
Boardman, Ohio
Apex Dermatology Mayfield Heights
Mayfield Heights, Ohio
Oregon Medical Research Center
Portland, Oregon
Oregon Dermatology and Research Center
Portland, Oregon
Clinical Research Philadelphia
Philadelphia, Pennsylvania
UPMC Department of Dermatology
Pittsburgh, Pennsylvania
Health Concepts
Rapid City, South Dakota
Advanced Research Experts PLLC
Nashville, Tennessee
Showing 40 of 160 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.